Can someone point me in the direction where it says the Parkinson trial's dosing is completed? I'll eat humble pie if that's the case.
I pointed out recently Gary saying only 2 weeks ago that the trial was only 25% completed.
He also said we won't be receiving SNT-5505 data until midway through Q2 and later changed that to midway/later Q2.
Hence why the SP is drifting, we have no near term catalyst and Platinum will continue to sell. The SP will drift towards 6c credit raise price and when we announce the commencement of the Myelodysplastic Syndrome and Hypertropic scarring trials platinum will sell into it.
This is why we should kick them to the curb, if possible, if we go it alone in the next credit raise. Although they are welcome to do whatever they like, they have massively diluted shareholders in the end game by capping the current SP.
SNT Price at posting:
6.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)